Muhammad Zaki Fadlullah Wilmot, Ph.D.
Dr. Muhammad Zaki Fadlullah Wilmot (Zaki Wilmot) earned his Bachelor of Science (Hons) from the University of Queensland, Australia. He subsequently joined Cancer Research Malaysia (CRM), a non-profit cancer research organization, as a bioinformatics research assistant. At CRM, his work focused on genomics and transcriptomic analyses of breast and head and neck cancers.
To further his expertise in cancer research, particularly computational oncology, Dr. Wilmot joined the Cancer Research UK (CRUK) Manchester Institute as a bioinformatics analyst. Under the mentorship of Professors Georges Lacaud, Ph.D., and Valerie Kouskoff, Ph.D., he utilized next-generation sequencing data to identify regulators of normal blood development and hematological cancers. He later pursued his Ph.D. under Prof. Lacaud at the University of Manchester, United Kingdom, where he combined multi-omics data with experimental approaches to investigate the mechanisms underlying hematopoietic stem cell emergence.
For his postdoctoral training, Dr. Wilmot joined the laboratory of Dr. Aik Choon Tan, Ph.D., at the Huntsman Cancer Institute (HCI), University of Utah. There, his research focused on leveraging real-world data and multi-omics datasets to identify factors associated with immunotherapy toxicity.
Currently, Dr. Wilmot is a Research Assistant Professor in the Department of Oncological Sciences at the University of Utah School of Medicine and HCI. His research focuses on understanding the mechanisms and biomarkers of immunotherapy-related toxicity, as well as advancing personalized clinical strategies, including blood-based liquid biopsy diagnostics in prostate cancer. Additionally, Dr. Wilmot is actively involved in mentoring Ph.D. students and early-career researchers and contributing to collaborative, interdisciplinary cancer research initiatives.
Research Interests
- Cancer Biology
- Biomarker discovery
- Multi-omics data integration
- Immune related adverse event
- Liquid biopsy
